On September 30, 2019, William C. Denby, III, a director of the Company and a member of the Audit Committee, Compensation Committee and Nominating and Governance Committee, notified Adamis Pharmaceuticals Corporation that for personal reasons, effective as of the close of business on September 30, 2019, he was resigning as a director of the Company and all subsidiaries, and that his resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies, practices or financial statements.